Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume – Still a Buy?

Bavarian Nordic (OTCMKTS:BVNRY) shares saw strong trading volume on Thursday. Approximately 5,993 shares changed hands during mid-day trading, an increase of 81% from the previous session’s volume of 3,305 shares. The stock last traded at $11.45 and had previously closed at $11.09.

Bavarian Nordic Stock Performance

The firm’s 50 day simple moving average is $10.53 and its 200 day simple moving average is $9.95. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of 11.90 and a beta of 1.25.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

About Bavarian Nordic

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.